Publications

  1. Jacobson SA, Morshed T, Dugger BN, Beach TG, Hentz JG, Adler CH, Shill HA, Sabbagh MN, Belden CM, Sue LI, Caviness JN, Hu C, Arizona Parkinson's Disease Consortium. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat Disord. 2014 Sep; 20(9):1009-14. Epub 2014 Jun 28.
    View PubMed
  2. Driver-Dunckley E, Adler CH, Hentz JG, Dugger BN, Shill HA, Caviness JN, Sabbagh MN, Beach TG, the Arizona Parkinson Disease Consortium. Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease. Parkinsonism Relat Disord. 2014 Aug 16.
    View PubMed
  3. Adler CH, Beach TG, Hentz JG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Sue LI, Jacobson SA, Belden CM, Dugger BN. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology. 2014 Jul 29; 83(5):406-12. Epub 2014 Jun 27.
    View PubMed
  4. Beach TG, Carew J, Serrano G, Adler CH, Shill HA, Sue LI, Sabbagh MN, Akiyama H, Cuenca N, Arizona Parkinson's Disease Consortium. Phosphorylated alpha-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects. Neurosci Lett. 2014 Jun 13; 571:34-8. Epub 2014 Apr 28
    View PubMed
  5. Dugger BN, Adler CH, Shill HA, Caviness J, Jacobson S, Driver-Dunckley E, Beach TG, Arizona Parkinson's Disease Consortium. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord. 2014 May; 20(5):525-9. Epub 2014 Feb 22.
    View PubMed
  6. Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014 May; 71(5):543-52.
    View PubMed
  7. Adler CH, Dugger BN, Hinni ML, Lott DG, Driver-Dunckley E, Hidalgo J, Henry-Watson J, Serrano G, Sue LI, Nagel T, Duffy A, Shill HA, Akiyama H, Walker DG, Beach TG. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology. 2014 Mar 11; 82(10):858-64. Epub 2014 Feb 05.
    View PubMed
  8. Dugger BN, Hentz JG, Adler CH, Sabbagh MN, Shill HA, Jacobson S, Caviness JN, Belden C, Driver-Dunckley E, Davis KJ, Sue LI, Beach TG. Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. J Neuropathol Exp Neurol. 2014 Mar; 73(3):244-52.
    View PubMed
  9. Lin TP, Adler CH, Hentz JG, Balcer LJ, Galetta SL, Devick S. Slowing of number naming speed by King-Devick test in Parkinson's disease. Parkinsonism Relat Disord. 2014 Feb; 20(2):226-9. Epub 2013 Oct 18.
    View PubMed
  10. Siderowf A, Pontecorvo MJ, Shill HA, Mintun MA, Arora A, Joshi AD, Lu M, Adler CH, Galasko D, Liebsack C, Skovronsky DM, Sabbagh MN. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. BMC Neurology. 2014; 14(1):79.
  11. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord. 2014; 29(5):634-50.
  12. Symanski C, Shill HA, Dugger B, Hentz JG, Adler CH, Jacobson SA, Driver-Dunckley E, Beach TG. Essential tremor is not associated with cerebellar Purkinje cell loss. Mov Disord. 2014; 29(4):496-500.
  13. Burgos K, Malenica I, Metpally R, Courtright A, Rakela B, Beach T, Shill H, Adler C, Sabbagh M, Villa S, Tembe W, Craig D, Van Keuren-Jensen K. Profiles of Extracellular miRNA in Cerebrospinal Fluid and Serum from Patients with Alzheimer's and Parkinson's Diseases Correlate with Disease Status and Features of Pathology. PLoS One. 2014; 9(5):e94839. Epub 2014 May 05.
    View PubMed
  14. Kellie JF, Higgs RE, Ryder JW, Major A, Beach TG, Adler CH, Merchant K, Knierman MD. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry. Sci Rep. 2014; 4:5797. Epub 2014 Jul 23.
    View PubMed
  15. Charles PD, Adler CH, Stacy M, Comella C, Jankovic J, Manack Adams A, Schwartz M, Brin MF. Cervical dystonia and pain: Characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014; 261(7):1309-19.
  16. Shneyder N, Adler CH, Hentz JG, Shill H, Caviness JN, Sabbagh MN, Beach TG, Driver-Dunckley E. Autonomic complaints in patients with restless legs syndrome. Sleep Med. 2013 Dec; 14(12):1413-6. Epub 2013 Sep 21.
    View PubMed
  17. Lewitt PA, Li J, Lu M, Beach TG, Adler CH, Guo L, Arizona Parkinson's Disease Consortium. 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. Mov Disord. 2013 Oct; 28(12):1653-60. Epub 2013 Jul 19.
    View PubMed
  18. Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, Ahlskog JE, Caselli RJ, Jacobson S, Sabbagh M, Adler C, Woodruff B, Beach TG, Iranzo A, Gelpi E, Santamaria J, Tolosa E, Singer C, Mash DC, Luca C, Arnulf I, Duyckaerts C, Schenck CH, Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013 Aug; 14(8):754-62. Epub 2013 Mar 07.
    View PubMed
  19. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013 Aug; 136(Pt 8):2419-31.
    View PubMed
  20. Mu L, Sobotka S, Chen J, Su H, Sanders I, Nyirenda T, Adler CH, Shill HA, Caviness JN, Samanta JE, Sue LI, Beach TG, Arizona Parkinson's Disease Consortium. Parkinson disease affects peripheral sensory nerves in the pharynx. J Neuropathol Exp Neurol. 2013 Jul; 72(7):614-23.
    View PubMed
  21. Beach TG, Adler CH, Dugger BN, Serrano G, Hidalgo J, Henry-Watson J, Shill HA, Sue LI, Sabbagh MN, Akiyama H, Arizona Parkinson's Disease Consortium. Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol. 2013 Feb; 72(2):130-6.
    View PubMed
  22. Mu L, Sobotka S, Chen J, Su H, Sanders I, Adler CH, Shill HA, Caviness JN, Samanta JE, Beach TG, Arizona Parkinson's Disease Consortium. Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol. 2013 Feb; 72(2):119-29.
    View PubMed
  23. Walker DG, Lue LF, Adler CH, Shill HA, Caviness JN, Sabbagh MN, Akiyama H, Serrano GE, Sue LI, Beach TG, Arizona Parkinson Disease Consortium. Changes in properties of serine 129 phosphorylated alpha-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol. 2013 Feb; 240:190-204. Epub 2012 Nov 28.
    View PubMed
  24. Henderson-Smith A, Chow D, Meechoovet B, Aziz M, Jacobson SA, Shill HA, Sabbagh MN, Caviness JN, Adler CH, Driver-Dunckley ED, Beach TG, Yin H, Dunckley T. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening. PLoS One. 2013; 8(10):e77711. Epub 2013 Oct 30.
    View PubMed
  25. Maarouf CL, Beach TG, Adler CH, Malek-Ahmadi M, Kokjohn TA, Dugger BN, Walker DG, Shill HA, Jacobson SA, Sabbagh MN, Roher AE, Arizona Parkinson's Disease Consortium. Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology. Biomark Insights. 2013; 8:19-28. Epub 2013 Mar 12
    View PubMed
  26. Lue LF, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, Sue LI, Caviness J, Sabbagh MN, Beach TG. Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol. 2012 Nov; 22(6):745-56. Epub 2012 Apr 12.
    View PubMed
  27. Annerino DM, Arshad S, Taylor GM, Adler CH, Beach TG, Greene JG. Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol. 2012 Nov; 124(5):665-80. Epub 2012 Sep 02.
    View PubMed
  28. Driver-Dunckley ED, Adler CH. Movement disorders and sleep. Neurol Clin. 2012 Nov; 30(4):1345-58.
    View PubMed
  29. Jiang H, He P, Adler CH, Shill H, Beach TG, Li R, Shen Y. Bid signal pathway components are identified in the temporal cortex with Parkinson disease. Neurology. 2012 Oct 23; 79(17):1767-73. Epub 2012 Sep 26.
    View PubMed
  30. Maarouf CL, Beach TG, Adler CH, Shill HA, Sabbagh MN, Wu T, Walker DG, Kokjohn TA, Roher AE, Arizona PD Consortium. Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurol Res. 2012 Sep; 34(7):669-76.
    View PubMed
  31. Mu L, Sobotka S, Chen J, Su H, Sanders I, Adler CH, Shill HA, Caviness JN, Samanta JE, Beach TG, Arizona Parkinson's Disease Consortium. Altered pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol. 2012 Jun; 71(6):520-30.
    View PubMed
  32. Siderowf A, Jennings D, Eberly S, Oakes D, Hawkins KA, Ascherio A, Stern MB, Marek K, PARS Investigators. Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord. 2012 Mar; 27(3):406-12. Epub 2012 Jan 11.
    View PubMed
  33. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012 Mar; 27(3):349-56. Epub 2012 Jan 24.
    View PubMed
  34. Dugger BN, Serrano GE, Sue LI, Walker DG, Adler CH, Shill HA, Sabbagh MN, Caviness JN, Hidalgo J, Saxon-Labelle M, Chiarolanza G, Mariner M, Henry-Watson J, Beach TG, the Arizona Parkinson's Disease Consortium. Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. J Parkinsons Dis. 2012 Jan 1; 2(1):57-65.
    View PubMed
  35. Shill HA, Adler CH, Beach TG. Pathology in essential tremor. Parkinsonism Relat Disord. 2012 Jan; 18 Suppl 1:S135-7.
    View PubMed
  36. Shill HA, Adler CH, Beach TG, Lue LF, Caviness JN, Sabbagh MN, Sue LI, Walker DG. Brain biochemistry in autopsied patients with essential tremor. Mov Disord. 2012 Jan; 27(1):113-7. Epub 2011 Oct 28.
    View PubMed
  37. *Damian A, Adler CH, Hentz JG, Shill HA, Caviness JN, Sabbagh MN, Evidente VGH, Beach TG, Driver-Dunckley E. Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease. Parkinsonism Relat Disord. 2012; 18(10):1089-93.
  38. Caviness JN, Adler CH, Hentz JG, Shill HA, Evidente VG, Driver-Dunckley ED, Sabbagh MN, Sue L, Beach TG. Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders. Clin Neurophysiol. 2011 Dec; 122(12):2426-32. Epub 2011 May 26.
    View PubMed
  39. Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 2011 Oct; 12(9):906-13. Epub 2011 Oct 05.
    View PubMed
  40. Adler CH, Crews D, Kahol K, Santello M, Noble B, Hentz JG, Caviness JN. Are the yips a task-specific dystonia or "golfer's cramp"? Mov Disord. 2011 Sep; 26(11):1993-6. Epub 2011 Jun 14.
    View PubMed
  41. Evidente VG, Premkumar AP, Adler CH, Caviness JN, Driver-Dunckley E, Lyons MK. Medication dose reductions after pallidal versus subthalamic stimulation in patients with Parkinson's disease. Acta Neurol Scand. 2011 Sep; 124(3):211-4. Epub 2010 Oct 25.
    View PubMed
  42. Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, Rodriguez-Oroz MC, Troster AI, Weintraub D. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord. 2011 Aug 15; 26(10):1814-24. Epub 2011 Jun 09.
    View PubMed
  43. Klassen BT, Hentz JG, Shill HA, Driver-Dunckley E, Evidente VG, Sabbagh MN, Adler CH, Caviness JN. Quantitative EEG as a predictive biomarker for Parkinson disease dementia. Neurology. 2011 Jul 12; 77(2):118-24. Epub 2011 Jun 01.
    View PubMed
  44. Adler CH, Hentz JG, Shill HA, Sabbagh MN, Driver-Dunckley E, Evidente VG, Jacobson SA, Beach TG, Boeve B, Caviness JN. Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome. Parkinsonism Relat Disord. 2011 Jul; 17(6):456-8. Epub 2011 Apr 08.
    View PubMed
  45. Caviness JN, Lue LF, Beach TG, Hentz JG, Adler CH, Sue L, Sadeghi R, Driver-Dunckley E, Evidente VG, Sabbagh MN, Shill HA, Walker DG. Parkinson's disease, cortical dysfunction, and alpha-synuclein. Mov Disord. 2011 Jul; 26(8):1436-42. Epub 2011 May 03.
    View PubMed
  46. Evidente VG, Adler CH, Sabbagh MN, Connor DJ, Hentz JG, Caviness JN, Sue LI, Beach TG. Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP? Parkinsonism Relat Disord. 2011 Jun; 17(5):365-71. Epub 2011 Mar 21.
    View PubMed
  47. Papay K, Mamikonyan E, Siderowf AD, Duda JE, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Weintraub D. Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability. Parkinsonism Relat Disord. 2011 Mar; 17(3):153-5. Epub 2010 Dec 24.
    View PubMed
  48. Adler CH, Shill HA, Beach TG. Essential tremor and Parkinson's disease: lack of a link. Mov Disord. 2011 Feb 15; 26(3):372-7. Epub 2011 Jan 31.
    View PubMed
  49. Caviness JN, Lue L, Adler CH, Walker DG. Parkinson's disease dementia and potential therapeutic strategies. CNS Neurosci Ther. 2011 Feb; 17(1):32-44. Epub 2010 Dec 28.
    View PubMed
  50. Damian AM, Jacobson SA, Hentz JG, Belden CM, Shill HA, Sabbagh MN, Caviness JN, Adler CH. The Montreal Cognitive Assessment and the mini-mental state examination as screening instruments for cognitive impairment: item analyses and threshold scores. Dement Geriatr Cogn Disord. 2011; 31(2):126-31. Epub 2011 Jan 29.
    View PubMed
  51. Jankovic J, Adler CH, Charles PD, Comella C, Stacy M, Schwartz M, Sutch SM, Brin MF, Papapetropoulos S. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2011; 11:140. Epub 2011 Nov 04.
    View PubMed
  52. Adler CH. Premotor symptoms and early diagnosis of Parkinson's disease. Int J Neurosci. 2011; 121 Suppl 2:3-8.
    View PubMed
  53. Adler CH, Beach TG. Variability of diffuse plaques and amyloid angiopathy in Parkinson's disease with mild cognitive impairment. Acta Neuropathol. 2010 Dec; 120(6):831. Epub 2010 Oct 13.
    View PubMed
  54. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grunblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wullner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med. 2010 Oct 6; 2(52):52ra73.
    View PubMed
  55. Evidente VG, Adler CH. An update on the neurologic applications of botulinum toxins. Curr Neurol Neurosci Rep. 2010 Sep; 10(5):338-44.
    View PubMed
  56. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG, Arizona Parkinson's Disease Consortium. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010 Jun; 119(6):689-702. Epub 2010 Mar 21.
    View PubMed
  57. Adler CH, Connor DJ, Hentz JG, Sabbagh MN, Caviness JN, Shill HA, Noble B, Beach TG. Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord. 2010 Apr 15; 25(5):642-6.
    View PubMed
  58. McKinnon J, Evidente V, Driver-Dunckley E, Premkumar A, Hentz J, Shill H, Sabbagh M, Caviness J, Connor D, Adler C. Olfaction in the elderly: a cross-sectional analysis comparing Parkinson's disease with controls and other disorders. Int J Neurosci. 2010 Jan; 120(1):36-9.
    View PubMed
  59. Adler CH. Mild cognitive impairment in Parkinson's disease. Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S81-2.
    View PubMed
  60. Cobb SA, Wider C, Ross OA, Mata IF, Adler CH, Rajput A, Rajput AH, Wu RM, Hauser R, Josephs KA, Carr J, Gwinn K, Heckman MG, Aasly JO, Lynch T, Uitti RJ, Wszolek ZK, Kapatos G, Farrer MJ. GCH1 in early-onset Parkinson's disease. Mov Disord. 2009 Oct 30; 24(14):2070-5.
    View PubMed
  61. Cobb SA, Wider C, Ross OA, Mata IF, Adler CH, Rajput A, Rajput AH, Wu RM, Hauser R, Josephs KA, Carr J, Gwinn K, Heckman MG, Aasly JO, Lynch T, Uitti RJ, Wszolek ZK, Kapatos G, Farrer MJ. GCH1 in darly-onset Parkinson's disease. Mov Disord. 2009 Oct 30; 24(14):2070-5.
    View PubMed
  62. Adler CH. Perioperative use of botulinum toxins. Toxicon. 2009 Oct; 54(5):654-7. Epub 2008 Dec 03.
    View PubMed
  63. Driver-Dunckley E, Connor D, Hentz J, Sabbagh M, Silverberg N, Hernandez J, Vedders L, Evidente VG, Shill H, Caviness J, Adler C. No evidence for cognitive dysfunction or depression in patients with mild restless legs syndrome. Mov Disord. 2009 Sep 15; 24(12):1840-2.
    View PubMed
  64. Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Stern MB, Voon V. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord. 2009 Jul 30; 24(10):1461-7.
    View PubMed
  65. Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, Caviness JN, Shill HA, Sue LI, Ziabreva I, Perry E, Ballard CG, Aarsland D, Walker DG, Beach TG. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):295-7.
    View PubMed
  66. Sabbagh MN, Sandhu SS, Farlow MR, Vedders L, Shill HA, Caviness JN, Connor DJ, Sue L, Adler CH, Beach TG. Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):229-33.
    View PubMed
  67. Almaraz AC, Driver-Dunckley ED, Woodruff BK, Wellik KE, Caselli RJ, Demaerschalk BM, Adler CH, Caviness JN, Wingerchuk DM. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. Neurologist. 2009 Jul; 15(4):234-7.
    View PubMed
  68. Vilarino-Guell C, Wider C, Soto-Ortolaza AI, Cobb SA, Kachergus JM, Keeling BH, Dachsel JC, Hulihan MM, Dickson DW, Wszolek ZK, Uitti RJ, Graff-Radford NR, Boeve BF, Josephs KA, Miller B, Boylan KB, Gwinn K, Adler CH, Aasly JO, Hentati F, Destee A, Characterization of DCTN1 genetic variability in neurodegeneration. Neurology. 2009 Jun 9; 72(23):2024-8.
    View PubMed
  69. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL III, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG. Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (Berl). 2009 Jun; 117(6):613-34.
    View PubMed
  70. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ, TEMPO Open-label Study Group. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009 Mar 15; 24(4):564-73.
    View PubMed
  71. Beach TG, White CL III, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, Sue LI, Sasse J, Bachalakuri J, Henry-Watson J, Akiyama H, Adler CH. Olfactory bulb alpha -synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol (Berl) 2009 Feb; 117(2):169-74.
    View PubMed
  72. Lyons MK, Adler CH, Bansberg SF, Evidente VGH. Spasmodic dysphonia may respond to bilateral thalamic deep brain stimulation. Afr J of Neurol Sci. 2009; 28(1):10-811.
  73. Alvarez MV, Driver-Dunckley EE, Caviness JN, Adler CH, Evidente VG. Case series of painful legs and moving toes: clinical and electrophysiologic observations. Mov Disord. 2008 Oct 30; 23(14):2062-6.
    View PubMed
  74. Sparks DL, Ziolkowski C, Connor D, Beach T, Adler C, Sabbagh M. Copper and cognition in Alzheimer's disease and Parkinson's disease. Cell Biology & Toxicology. 2008 Oct; 24(5):426-30.
    View PubMed
  75. Ludlow CL, Adler CH, Berke GS, Bielamowicz SA, Blitzer A, Bressman SB, Hallett M, Jinnah HA, Juergens U, Martin SB, Perlmutter JS, Sapienza C, Singleton A, Tanner CM, Woodson GE. Research priorities in spasmodic dysphonia. Otolaryngol Head Neck Surg. 2008 Oct; 139(4):495-505.
    View PubMed
  76. Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, Leverenz JB, Roncaroli F, Buttini M, Hladik CL, Sue LI, Noorigian JV, Adler CH. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol. 2008 Sep; 116(3):277-88. Epub 2008 Jul 15.
    View PubMed
  77. Stamper C, Siegel A, Liang WS, Pearson JV, Stephan DA, Shill H, Connor D, Caviness JN, Sabbagh M, Beach TG, Adler CH, Dunckley T. Neuronal gene expression correlates of Parkinson's disease with dementia. Mov Disord. 2008 Aug 15; 23(11):1588-95.
    View PubMed
  78. Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin MC, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008 Jun; 63(6):743-50.
    View PubMed
  79. Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK, Parkinson Study Group, Leurgans S. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008 Apr 15; 23(5):690-9.
    View PubMed
  80. Shill HA, Adler CH, Sabbagh MN, Connor DJ, Caviness JN, Hentz JG, Beach TG. Pathologic findings in prospectively ascertained essential tremor subjects. Neurology. 2008 Apr 15; 70(16 Pt 2):1452-5.
    View PubMed
  81. Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, Dalsing-Hernandez JE, Lue LF, Caviness JN, Connor DJ, Sabbagh MN, Walker DG. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 2008 Apr; 115(4):445-51. Epub 2007 Nov 06.
    View PubMed
  82. McKinnon JH, Demaerschalk BM, Caviness JN, Wellik KE, Adler CH, Wingerchuk DM. Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders? Neurologist. 2007 Nov; 13(6):382-5.
    View PubMed
  83. Beach TG, Sue LI, Walker DG, Lue LF, Connor DJ, Caviness JN, Sabbagh MN, Adler CH. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol (Berl) 2007 Oct; 114(4):419-24. Epub 2007 Jul 17.
    View PubMed
  84. Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, Krahn L, Adler CH. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):249-55.
    View PubMed
  85. Caviness JN, Hentz JG, Evidente VG, Driver-Dunckley E, Samanta J, Mahant P, Connor DJ, Sabbagh MN, Shill HA, Adler CH. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. Parkinsonism Relat Disord. 2007 Aug; 13(6):348-54. Epub 2007 Mar 08.
    View PubMed
  86. Trosch RM, Adler CH, Pappert EJ. Botulinum toxin type B (Myobloc(R)) in subjects with hemifacial spasm: Results from an open-label, dose-escalation safety study. Mov Disord. 2007 Jul 15; 22(9):1258-64.
    View PubMed
  87. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH. Defining mild cognitive impairment in Parkinson's disease. Mov Disord. 2007 Jul 15; 22(9):1272-7.
    View PubMed
  88. Melquist S, Craig DW, Huentelman MJ, Crook R, Pearson JV, Baker M, Zismann VL, Gass J, Adamson J, Szelinger S, Corneveaux J, Cannon A, Coon KD, Lincoln S, Adler C, Tuite P, Calne DB, Bigio EH, Uitti RJ, Wszolek ZK, Golbe LI, Caselli RJ, Graff-Radford N, Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. Am J Hum Genet. 2007 Apr; 80(4):769-78. Epub 2007 Mar 08.
    View PubMed
  89. Snyder CH, Adler CH. The patient with Parkinson's disease: part I-treating the motor symptoms; part II-treating the nonmotor symptoms. J Am Acad Nurse Pract. 2007 Apr; 19(4):179-97.
    View PubMed
  90. Toft M, Mata IF, Ross OA, Kachergus J, Hulihan MM, Haugarvoll K, Stone JT, Blazquez M, Gibson JM, Aasly JO, White LR, Lynch T, Adler CH, Gwinn-Hardy K, Farrer MJ. Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. Mov Disord. 2007 Feb 15; 22(3):389-92.
    View PubMed
  91. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007 Jan 2; 68(1):20-8.
    View PubMed
  92. Sabbagh MN, Lahti T, Connor DJ, Caviness JN, Shill H, Vedders L, Mahant P, Samanta J, Burns RS, Evidente VG, Driver-Dunckley E, Reisberg B, Bircea S, Adler CH. Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease. Dement Geriatr Cogn Disord. 2007; 24(5):327-34. Epub 2007 Sep 13.
    View PubMed
  93. Langbehn DR, Paulsen JS, Hedges P, McCusker E, Pearce S, Trent R, Abwender D, Como P, Gardiner I, Hickey C, Kayson E, Kieburtz K, Marshall F, Pearson N, Shoulson I, Zimmerman C, Louis E, Marder K, Moskowitz C, Polanco C, Taylor S, Zubin N, Brown C, Predictors of diagnosis in Huntington disease. Neurology. 2007; 68(20):1710-7.
    View PubMed
  94. Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
    View PubMed
  95. Driver-Dunckley E, Evidente VG, Adler CH, Hillman R, Hernandez J, Fletcher G, Lyons MK. Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation. Mov Disord. 2006 Aug; 21(8):1287-9.
    View PubMed
  96. Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I, Parkinson Study Group. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord. 2006 May; 21(5):616-23.
    View PubMed
  97. Caviness JN, Liss JM, Adler C, Evidente V. Analysis of high-frequency electroencephalographic-electromyographic coherence elicited by speech and oral nonspeech tasks in Parkinson's disease. J Speech Lang Hear Res. 2006 Apr; 49(2):424-38.
    View PubMed
  98. Caviness JN, Shill HA, Sabbagh MN, Evidente VG, Hernandez JL, Adler CH. Corticomuscular coherence is increased in the small postural tremor of Parkinson's disease. Mov Disord. 2006 Apr; 21(4):492-9.
    View PubMed
  99. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006 Mar 14; 66(5):664-71. Epub 2006 Feb 15.
    View PubMed
  100. Blindauer K, Shoulson I, Oakes D, Kieburtz K, Schwid S, Fahn S, Stern M, Goetz C, Nutt J, Goren S, Sayag N, Scolnik M, Levy R, Eyal E, Salzman P, Pagano M, Parkinson Study Group. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb; 63(2):210-6.
    View PubMed
  101. Mata IF, Bodkin CL, Adler CH, Lin SC, Uitti RJ, Farrer MJ, Wszolek ZK. Genetics of restless legs syndrome. Parkinsonism Relat Disord. 2006 Jan; 12(1):1-7.
    View PubMed
  102. Sparks DL, Petanceska S, Sabbagh M, Connor D, Soares H, Adler C, Lopez J, Ziolkowski C, Lochhead J, Browne P. Cholesterol, copper and A beta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Current Alzheimer Research. 2005 Dec; 2(5):527-39.
    View PubMed
  103. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W, Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005 Nov 8; 65(9):1423-9.
    View PubMed
  104. Thorpy MJ, Adler CH. Parkinson's disease and sleep. Neurol Clin. 2005 Nov; 23(4):1187-208.
    View PubMed
  105. Sabbagh MN, Silverberg N, Bircea S, Majeed B, Samant S, Caviness JN, Reisberg B, Adler CH. Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease? Parkinsonism Relat Disord. 2005 Aug; 11(5):311-5.
    View PubMed
  106. Adler CH, Thorpy MJ. Sleep issues in Parkinson's disease. Neurology. 2005 Jun 28; 64(12 Suppl 3):S12-S20.
    View PubMed
  107. Adler CH. Nonmotor complications in Parkinson's disease. Mov Disord. 2005 Apr; 20(Suppl 11):S23-9.
    View PubMed
  108. Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, Shoulson I, Wexler NS, Young AB, Zhao H, The United States-Venezuela Huntington's Disease Collaborative Research Group, The Huntington Study Group. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord. 2005 Mar; 20(3):293-7.
    View PubMed
  109. Wunderlich GR, Evans KR, Sills T, Pollentier S, Reess J, Allen RP, Hening W, Walter AS, The International Restless Legs Syndrome Study Group. An item response analysis of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep med. 2005 Mar; 6(2):131-9.
  110. Toft M, Aasly J, Bisceglio G, Adler CH, Uitti RJ, Krygowska-Wajs A, Lynch T, Wszolek ZK, Farrer MJ. Parkinsonism, FXTAS, and FMR1 premutations. Mov Disord. 2005 Feb; 20(2):230-3.
    View PubMed
  111. Adler CH, Bansberg SF, Krein-Jones K, Hentz JG. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. Mov Disord. 2004 Sep; 19(9):1075-9.
    View PubMed
  112. Adler CH, Bansberg SF, Hentz JG, Ramig LO, Buder EH, Witt K, Edwards BW, Krein-Jones K, Caviness JN. Botulinum toxin type A for treating voice tremor. Arch Neurol. 2004 Sep; 61(9):1416-20.
    View PubMed
  113. Pittock SJ, Parrett T, Adler CH, Parisi JE, Dickson DW, Ahlskog JE. Neuropathology of primary restless leg syndrome: absence of specific tau- and alpha-synuclein pathology. Mov Disord. 2004 Jun; 19(6):695-9.
    View PubMed
  114. Adler CH, Hauser RA, Sethi K, Caviness JN, Marlor L, Anderson WM, Hentz JG. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology. 2004 Apr 27; 62(8):1405-7.
    View PubMed
  115. Beach TG, Walker DG, Sue LI, Newell A, Adler CC, Joyce JN. Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers. J Neuropathol Exp Neurology. 2004 Apr; 63(4):329-37.
    View PubMed
  116. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004; 351:2498-2508.
    View PubMed
  117. Van Gemmert AWA, Adler CH, Stelmach GE. Parkinson's disease patients undershoot target size in handwriting and similar tasks. Journal of Neurology, Neurosurgery & Psychiatry. 2003 Nov; 74(11):1502-8.
    View PubMed
  118. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. alpha-synuclein locus triplication causes Parkinson's disease. Science. 2003 Oct 31; 302(5646):841.
    View PubMed
  119. Caviness JN, Adler CH, Sabbagh MN, Connor DJ, Hernandez JL, Lagerlund TD. Abnormal corticomuscular coherence is associated with the small amplitude cortical myoclonus in Parkinson's disease. Mov Disord. 2003 Oct; 18(10):1157-62.
    View PubMed
  120. Evidente VG, Caviness JN, Adler CH. Case studies in movement disorders. Semin Neurol. 2003 Sep; 23(3):277-84.
    View PubMed
  121. Romero DH, Van Gemmert AWA, Adler CH, Bekkering H, Stelmach GE. Altered aiming movements in Parkinson's disease patients and elderly adults as a function of delays in movement onset. Exp Brain Res. 2003 Jul; 151(2):249-61.
    View PubMed
  122. Beach TG, Sue L, Scott S, Layne K, Newell A, Walker D, Baker M, Sahara N, Yen SH, Hutton M, Caselli R, Adler C, Connor D, Sabbagh M. Hippocampal sclerosis dementia with tauopathy. Brain Pathol. 2003 Jul; 13(3):263-78.
    View PubMed
  123. Romero DH, Van Gemmert AWA, Adler CH, Bekkering H, Stelmach GE. Time delays prior to movement alter the drawing kinematics of elderly adults. Human Movement Science. 2003 Apr; 22(2):207-20.
    View PubMed
  124. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord. 2003 Mar; 18(3):287-93.
    View PubMed
  125. Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T, The Dystonia Study Group. Rating scales for dystonia: A multicenter assessment. Mov Disorders. 2003; 18:303-12.
  126. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montlaisir J, the participants in the RLS Diagnosis Epidemiology workshop at the NIH, in collaboration with members of the International RLS Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health Sleep Medicine. 2003; 4:101-19.
  127. Adler CH, Thorpy MJ. Awake and Involved: Addressing excessive daytime sleepiness in patients with Parkinson’s disease, Overview of Parkinson’s disease (Review Article). The Treatment Reporter Neurology. 2003(Part 1).
  128. Thorpy MJ, Adler CH. Awake and Involved: Addressing excessive daytime sleepiness in patients with Parkinson’s disease, Sleep issues in Parkinson’s disease (Review Article). The Treatment Reporter Neurology. 2003; Part 2.
  129. The International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group Rating Scale for Restless Legs Syndrome. Sleep Medicine. 2003;4:121-32.
    View PubMed
  130. Smith AM, Adler CH, Crews D, Wharen RE, Laskowski ER, Barnes K, Bell CV, Pelz D, Brennan RD, Smith J, Sorenson MC, Kaufman KR. The 'Yips' in golf - A continuum between a focal dystonia and choking. Sports Med. 2003; 33(1):13-31.
    View PubMed
  131. Contreras-Vidal JL, Teulings HL, Stelmach GE, Adler CH. Adaptation to changes in vertical display gain during handwriting in Parkinson's disease patients, elderly and young controls. Parkinsonism & Related Disorders. 2002 Dec; 9(2):77-84.
    View PubMed
  132. Adler CH, Hentz JG, Joyce JN, Beach T, Caviness JN. Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism & Related Disorders. 2002 Dec; 9(2):103-10.
    View PubMed
  133. Liss JM, Spitzer SM, Caviness JN, Adler C. The effects of familiarization on intelligibility and lexical segmentation in hypokinetic and ataxic dysarthria. J Acoust Soc Am. 2002 Dec; 112(6):3022-30.
    View PubMed
  134. Joyce JN, Ryoo HL, Beach TB, Caviness JN, Stacy M, Gurevich EV, Reiser M, Adler CH. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D-3 and not D-2 receptors. Brain Res. 2002 Nov 15; 955(1-2):138-52.
    View PubMed
  135. Korczyn AD, Thalamas C, Adler CH. Dosing with ropinirole in a clinical setting. Acta Neurol Scand. 2002 Oct; 106(4):200-4.
    View PubMed
  136. Caviness JN, Adler CH, Beach TG, Wetjen KL, Caselli RJ. Small-amplitude cortical myoclonus in Parkinson's disease: Physiology and clinical observations. Mov Disord. 2002 Jul; 17(4):657-62.
    View PubMed
  137. Kompoliti K, Adler CH, Raman R, Pincus JH, Leibowitz MT, Ferry JJ, Blasucci L, Caviness JN, Leurgans S, Chase WM, Yones LC, Tan E, Carvey P, Goetz CG. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
    View PubMed
  138. Vernino S, Tuite P, Adler CH, Meschia JF, Boeve BF, Boasberg P, Parisi JE, Lennon VA. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol. 2002 May; 51(5):625-30.
    View PubMed
  139. Teulings HL, Contreras-Vidal JL, Stelmach GE, Adler CH. Adaptation of handwriting size under distorted visual feedback in patients with Parkinson's disease and elderly and young controls. Journal of Neurology, Neurosurgery & Psychiatry. 2002 Mar; 72(3):315-24.
    View PubMed
  140. Adler CH. Relevance of motor complications in Parkinson's disease. Neurology. 2002 Feb 26; 58(4 Suppl 1):S51-6.
    View PubMed
  141. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Hentz JG, Manfred MS, Muenter D. Motor unit number estimates in idiopathic Parkinson's disease. Parkinsonism Relat Disord. 2002 Jan; 8(3):161-4.
    View PubMed
  142. Adler CH, Factor SA, Brin M, Sethi KD. Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia. Mov Disord. 2002 Jan; 17(1):158-61.
    View PubMed
  143. Caviness JN, Adler CH, Beach TG, Wetjen KL, Caselli RJ. Myoclonus in Lewy body disorders. Adv Neurol. 2002; 89:23-30.
    View PubMed
  144. Adler CH. Diagnosing and treating restless legs syndrome. Women's Health Orthopedic Edition. 2002; 5:54-8.
    View PubMed
  145. Adler CH. Managing movement disorders with botulinum toxins: An effective approach for dystonia, tics, tremor, and hemifacial spasm (Review Article). Women’s Health in Primary Care. 2002; 5:707-19.
  146. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson’s disease: The TEMPO study. Arch Neurol. 2002; 59:1937-43.
    View PubMed
  147. Adler CH, Joyce JN. Collaboration Amongst Arizona Parkinson’s Disease Research Centers-Parkinson’s Disease Center Without Walls (Review Article). AZ Parkinson’s Disease Report. 2002.
  148. Evidente VG, Caviness JN, Adler CH, Gwinn-Hardy KA, Pratley RE. Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss. Mov Disord. 2001 Sep; 16(5):924-7.
    View PubMed
  149. Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I, Huntington Study Group. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology. 2001 Aug 28; 57(4):658-62.
    View PubMed
  150. Joyce JN, Ryoo H, Gurevich EV, Adler C, Beach T. Ventral striatal D(3) receptors and Parkinson's Disease. Parkinsonism Relat Disord. 2001 Jul; 7(3):225-230.
    View PubMed
  151. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, Dubinsky RM, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001 Jun 12; 56(11):1523-8.
    View PubMed
  152. Alberts JL, Adler CH, Saling M, Stelmach GE. Prehension patterns in restless legs syndrome patients. Parkinsonism & Related Disorders. 2001 Apr; 7(2):143-148.
    View PubMed
  153. Shoulson I, Penney J, McDermott M, Schwid S, Kayson E, Chase T, Fahn S, Greenamyre JT, Lang A, Siderowf A, Pearson N, Harrison M, Rost E, Colcher A, Lloyd M, Matthews M, Pahwa R, McGuire D, Lew MF, Schuman S, Marek K, Broshjeit S, Factor S, Brown D, A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology. 2001 Feb 27; 56(4):455-62.
    View PubMed
  154. Adler CH. Ten commonly asked questions about initiating treatment for Parkinson’s disease (Review Article). The Neurologist. 2001; 7(3):188-92.
  155. Adler CH. Diagnosing and treating restless legs syndrome (Review Article). Women’s Health In Primary Care. 2001; 4:224-8.
  156. Adler CH. Diagnosing and treating restless legs syndrome (Review Article). Women’s Health Gynecology Edition. 2001; 1:371-8.
  157. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Hentz JG, Muenter MD. Motor Unit Number Estimates in Idiopathic Parkinson’s Disease. Parkinsonism and Related Disorders. 2001; 8:161-4.
  158. Pennachio DL, Consultants. Parkinson’s disease: Progress along the continuum of care (Review Article). Patient Care. 2000 Dec.
  159. Adler CH. Questions and answers about clinical trials (Review Article). Nightwalkers: Restless Legs Syndrome Newsletter. 2000 Nov.
  160. Alberts JL, Saling M, Adler CH, Stelmach GE. Disruptions in the reach-to-grasp actions of Parkinson's patients. Exp Brain Res. 2000 Oct; 134(3):353-62.
    View PubMed
  161. Adler CH. Strategies for controlling dystonia. Overview of therapies that may alleviate symptoms. Postgrad Med. 2000 Oct; 108(5):151-2, 155-6, 159-60.
    View PubMed
  162. Cooper C, Evidente VG, Hentz JG, Adler CH, Caviness JN, Gwinn-Hardy K. The effect of temperature on hand function in patients with tremor. J Hand Ther. 2000 Oct-Dec; 13(4):276-88.
    View PubMed
  163. Liss JM, Spitzer SM, Caviness JN, Adler C, Edwards BW. Lexical boundary error analysis in hypokinetic and ataxic dysarthria. J Acoust Soc Am. 2000 Jun; 107(6):3415-24.
    View PubMed
  164. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Reiners CA, Hentz JG, Muenter MD. Motor unit changes in sporadic idiopathic Parkinson's disease. Mov Disord. 2000 Mar; 15(2):238-43.
    View PubMed
  165. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O'Brien CF, Molho ES, Factor SA. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000 Mar-Apr; 23(2):75-81.
    View PubMed
  166. Evidente VG, Adler CH, Caviness JN, Hentz JG, Gwinn-Hardy K. Amantadine is beneficial in restless legs syndrome. Mov Disord. 2000 Mar; 15(2):324-7.
    View PubMed
  167. Gwinn-Hardy KA, Adler CH, Weaver AL, Fish NM, Newman SJ. Effect of hormone variations and other factors on symptom severity in women with dystonia. Mayo Clin Proc. 2000 Mar; 75(3):235-40.
    View PubMed
  168. Gwinn-Hardy KA, Crook R, Lincoln S, Adler CH, Caviness JN, Hardy J, Farrer M. A kindred with Parkinson's disease not showing genetic linkage to established loci. Neurology. 2000 Jan 25; 54(2):504-7.
    View PubMed
  169. Caviness JN, Gwinn-Hardy K, Adler CH, Muenter MD. Electrophysical observations in hereditary Parkinsonism-dementia with Lewy body pathology. Mov Disord. 2000 Jan; 15(1):140-145.
    View PubMed
  170. Adler CH, Kumar R. Pharmacological and surgical options for the treatment of cervical dystonia. Neurology. 2000; 55(12 Suppl 5):S9-14.
    View PubMed
  171. Joyce JN, Adler CH. Research for new treatment of Parkinson’s disease (Review Article). Southwest Parkinson Report. 2000 Spr/Sum.
  172. Adler CH. Review of New-Onset Tic Disorders in Adults (Review Article). Journal Watch Neurology. 2000; 2:73-4.
  173. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I, Caviness JN, The Huntington Study Group. Rate of functional decline in Huntington’s disease. Neurology. 2000; 54:452-8.
    View PubMed
  174. Spitzer SM, Liss JM, Caviness JN, Adler C. The effects of familiarization on listener perception of hypokinetic and ataxic dysarthric speech. Journal of Medical Speech-Language Pathology. 2000; 8:285-93.
  175. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22; 53(7):1431-8.
    View PubMed
  176. Weiss PH, Stelmach GE, Chaiken A, Adler CH. Use of advance information for complex movements in Parkinson's disease. Parkinsonism & Related Disorders. 1999 Apr-May; 5(1-2):19-25.
  177. Adler CH. Differential diagnosis of Parkinson's disease. Med Clin North Am. 1999 Mar; 83(2):349-67.
    View PubMed
  178. Evidente VG, Adler CH. How to help patients with restless legs syndrome. Discerning the indescribable and relaxing the restless. Postgrad Med. 1999 Mar; 105(3):59-61, 65-6, 73-4.
    View PubMed
  179. Evidente VG, Gwinn-Hardy K, Caviness JN, Alder CH. Risperidone is effective in severe hemichorea/hemiballismus. Mov Disord. 1999 Mar; 14(2):377-9.
    View PubMed
  180. Farrer M, Gwinn-Hardy K, Muenter M, DeVrieze FW, Crook R, Perez-Tur J, Lincoln S, Maraganore D, Adler C, Newman S, MacElwee K, McCarthy P, Miller C, Waters C, Hardy J. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet. 1999 Jan; 8(1):81-5.
    View PubMed
  181. Evidente VG, Adler CH, Caviness JN, Gwinn-Hardy K. A pilot study on the motor effects of rimantadine in Parkinson's disease. Clin Neuropharmacol. 1999 Jan-Feb; 22(1):30-2.
    View PubMed
  182. Adler CH. Botulinum toxin: Overview and use in tremor disorders (Review Article). International Tremor Foundation Newsletter. 1998 Oct.
  183. Liss JM, Spitzer S, Caviness JN, Adler C, Edwards B. Syllabic strength and lexical boundary decisions in the perception of hypokinetic dysarthric speech. J Acoust Soc Am. 1998 Oct; 104(4):2457-66.
    View PubMed
  184. Evidente VG, Adler CH, Caviness JN, Gwinn KA. Effective treatment of orthostatic tremor with gabapentin. Mov Disord. 1998 Sep; 13(5):829-31.
    View PubMed
  185. Sethi KD, Obrien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL, Sanchezramos J, Bertoni JM, Hauser RA. Ropinirole for the treatment of early Parkinson-disease - a 12-month experience. Arch Neurol. 1998 Sep; 55(9):1211-1216.
    View PubMed
  186. Adler CH, Singer C, O'Brien C, Hauser RA, Lew MF, Marek KL, Dorflinger E, Pedder S, Deptula D, Yoo K. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol. 1998 Aug; 55(8):1089-95.
    View PubMed
  187. Johnstone SJ, Adler CH. Headache and facial pain responsive to botulinum toxin: an unusual presentation of blepharospasm. Headache. 1998 May; 38(5):366-8.
    View PubMed
  188. Kurth MC, Adler CH. COMT inhibition: a new treatment strategy for Parkinson's disease. Neurology. 1998 May; 50(5 Suppl 5):S3-14.
    View PubMed
  189. Evidente VG, Adler CH, Giannini C, Conley CR, Parisi JE, Fletcher GP. Erdheim-Chester disease with extensive intraaxial brain stem lesions presenting as a progressive cerebellar syndrome. Mov Disord. 1998 May; 13(3):576-81.
    View PubMed
  190. Caviness JN, Adler CH, Newman S, Caselli RJ, Muenter MD. Cortical myoclonus in levodopa-responsive parkinsonism. Mov Disord. 1998 May; 13(3):540-4.
    View PubMed
  191. Adler CH, Gwinn KA, Newman S. Olfactory function in restless legs syndrome. Mov Disord. 1998 May; 13(3):563-5.
    View PubMed
  192. Shannon KM, Penn RD, Kroin JS, Adler CH, Janko KA, York M, Cox SJ. Stereotactic pallidotomy for the treatment of Parkinson's disease. Efficacy and adverse effects at 6 months in 26 patients. Neurology. 1998 Feb; 50(2):434-8.
    View PubMed
  193. Evidente VG, Adler CH. Hemifacial spasm and other craniofacial movement disorders. Mayo Clin Proc. 1998 Jan; 73(1):67-71.
    View PubMed
  194. Adler CH. COMT inhibitors: novel treatments for Parkinson's disease. CNS Spectrums. 1998; 3(2):53-56.
  195. Johnstone S, Adler CH. Headache and facial pain: Response to botulinum toxin (Review Article). Benign Essential Blepharospasm Newsletter. 1998; 17(5):5.
  196. Tresilian JR, Stelmach GE, Adler CH. Stability of reach-to-grasp movement patterns in Parkinson's disease. Brain. 1997 Nov; 120(Pt 11):2093-111.
    View PubMed
  197. Uitti RJ, Wharen RE Jr, Turk MF, Lucas JA, Finton MJ, Graff-Radford NR, Boylan KB, Goerss SJ, Kall BA, Adler CH, Caviness JN, Atkinson EJ. Unilateral pallidotomy for Parkinson's disease: comparison of outcome in younger versus elderly patients. Neurology. 1997 Oct; 49(4):1072-7.
    View PubMed
  198. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology. 1997 Aug; 49(2):393-9.
    View PubMed
  199. Teulings HL, Contreras-Vidal JL, Stelmach GE, Adler CH. Parkinsonism reduces coordination of fingers, wrist, and arm in fine motor control. Exp Neurol. 1997 Jul; 146(1):159-70.
    View PubMed
  200. O'Neill MA, Gwinn KA, Adler CH. Biofeedback for writer's cramp. Am J Occup Ther. 1997 Jul-Aug; 51(7):605-7.
    View PubMed
  201. Evidente VGH, Adler CH. Pharmacologic options for managing Parkinson's-disease. Hosp Formul. 1997 Jun; 32(6):594-610.
  202. Adler CH, Caviness JN. Dystonia secondary to electrical injury: surface electromyographic evaluation and implications for the organicity of the condition. J Neurol Sci. 1997 May 29; 148(2):187-92.
    View PubMed
  203. Adler CH. Treatment of restless legs syndrome with gabapentin. Clin Neuropharmacol. 1997 Apr; 20(2):148-51.
    View PubMed
  204. Kurth MC, Adler CH, Sthilaire M, Singer C, Waters C, Lewitt P, Chernik DA, Dorflinger EE, Yoo K, Lieberman AN, Brewer M, Sainthilaire M, Pery LM, Thomas C, Turpin L, Obrien CF, Seeberger LC, Duncan KL, Caviness JN, Douglas M, Wheeler K, Riley D, Rainey P, Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations - a multicenter, double blind, randomized, placebo-controlled trial. Neurology. 1997 Jan; 48(1):81-87.
    View PubMed
  205. Lieberman A, Caviness JN, The Pramipexole Study Group. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controled, parallel-group study. Neurology. 1997; 49(162-8).
  206. Adler CH, Joyce J. Parkinson's disease and your brain (Review Article). Arizona Parkinson Report Summer, 1997.
  207. Evidente V, Adler CH. Current management of Parkinson's disease. Formulary. 1997; 32:594-610.
  208. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol. 1996 Jun; 19(3):202-12.
    View PubMed
  209. Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI, Stern MB, Hiner BC, Lieberman A, Pfeiffer RF, Rodnitzky RL, Waters CH, Muenter MD, Adler CH, Morris JL. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology. 1996 Apr; 46(4):1062-5.
    View PubMed
  210. Adler CH, Zimmerman RS, Lyons MK, Simeone F, Brin MF. Perioperative use of botulinum toxin for movement disorder-induced cervical spine disease. Mov Disord. 1996 Jan; 11(1):79-81.
    View PubMed
  211. Adler CH, Wrabetz LG. Lesch-Nyhan variant: Dystonia, ataxia, near-normal intelligence, and no self-mutilation. Movement Disorders. 1996; 11:583-4.
    View PubMed
  212. Weiss P, Stelmach GE, Adler CH, Waterman C. Parkinsonian arm movements as altered by task difficulty. Parkinson's Disease and Related Disorders. 1996; 2:215-23.
  213. Adler CH, Stern MB, Shils J, Stecker MM. Movement analysis in generalized and hemiparkinsonism. J Human Movement Studies. 1995; 29:51-62.
  214. Adler CH. Why? I don't know! (Review Article). NSTA Newsletter 4 1995; 12(1).
  215. Pestronk A, Choksi R, Bieser K, Goldstein JM, Adler CH, Caselli RJ, George EB. Treatable gait disorder and polyneuropathy associated with high titer serum IgM binding to antigens that copurify with myelin-associated glycoprotein. Muscle & Nerve. 1994 Nov; 17(11):1293-300.
    View PubMed
  216. Adler CH, Wrabetz L, Brin MF, Hurtig HI. Cerebellar ataxia, dystonia, and tremor within a family: variable phenotypes of a single genetic disorder? Mov Disord. 1994 Mar; 9(2):155-60.
    View PubMed
  217. Stern MB, Doty RL, Dotti M, Corcoran P, Crawford D, McKeown DA, Adler CH, Gollomp S, Hurtig H. Olfactory function in Parkinson's disease subtypes. Neurology. 1994; 44:266-8.
    View PubMed
  218. Bernardi B, Zimmerman RA, Savino PJ, Adler C. Magnetic resonance tomographic angiography in the investigation of hemifacial spasm. Neuroradiology. 1993; 35(8):606-11.
    View PubMed
  219. Castiello U, Bennett KMB, Adler CH, Stelmach GE. Perturbation of the grasp component of a prehension movement in a patient with hemi-Parkinson disease. Neuropsychologia. 1993; 31:717-723.
    View PubMed
  220. Bennett KMB, Adler CH, Stelmach GE, Castiello U. A kinematic study of the reach to grasp movement in a patient with hemi-Parkinson disease. Neuropsychologia. 1993; 31:709-716.
    View PubMed
  221. Adler CH. Mechanism of action of botulinum toxin (Review Article). NSTA Newsletter 4 1993; 10(2).
  222. Adler CH, Zimmerman RA, Savino PJ, Bernardi B, Bosley TM, Sergott RC. Hemifacial spasm: evaluation by magnetic resonance imaging and magnetic resonance tomographic angiography. Ann Neurol. 1992 Oct; 32(4):502-6.
    View PubMed
  223. Dodick D, Adler CH. Tourette's syndrome. Current approaches to recognition and management. Postgrad Med. 1992 Oct; 92(5):299-302, 305-8.
    View PubMed
  224. Adler CH, Hurtig HI, Jacobson MP, Brooks ML. CPC: a woman with lung and brain masses. J Neuroimaging. 1992; 2:97-101.
  225. Arai H, Schmidt ML, Lee VMY, Hurtig HI, Greenberg BD, Adler CH, Trojanowski JQ. Epitope analysis of senile plaque components in the hippocampus. Neurology. 1992; 42:1315-1322.
    View PubMed
  226. Adler CH. Dystonia, clinical overview. Clin Semin Mov Disord. 1992; 1:14-16.
  227. Adler CH. Botulinum toxin A therapy in dystonia. Hosp Pract (Off Ed). 1991 Aug 15; 26(8):35, 38, 41-2.
    View PubMed
  228. Adler CH, Galetta SL. Oculo-facial-skeletal myorhythmia in Whipple disease: treatment with ceftriaxone. Ann Intern Med. 1990 Mar 15; 112(6):467-9.
    View PubMed
  229. Adler CH, Stern MB, Brooks ML. Parkinsonism secondary to bilateral striatal fungal abscesses. Mov Disord. 1989; 4(4):333-7.
    View PubMed
  230. Adler CH, Meller E, Goldstein M. Receptor reserve at functional alpha-2 adrenergic autoreceptors in the rat cerebral cortex. J Pharmacol Exp Ther. 1987; 240:508-515.
    View PubMed
  231. Meller E, Helmer-Matyjek E, Bohmaker K, Adler CH, Friedhoff AJ, Goldstein M. Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists. Eur J Pharmacol. 1986 Apr 16; 123(2):311-4.
    View PubMed
  232. Goldstein M, Kusano N, Adler C, Meller E. Characterization of central neuropeptide Y receptor binding sites and possible interactions with alpha 2-adrenoceptors. Prog Brain Res. 1986; 68:331-5.
    View PubMed
  233. Adler CH, Meller E, Goldstein M. Recovery of alpha 2-adrenoceptor binding and function after irreversible inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Eur J Pharmacol. 1985 Oct 8; 116(1-2):175-8.
    View PubMed
  234. Adler CH, Robin M, Adler MW. Tolerance to morphine-induced mydriasis in the rat pupil. Life Sci. 1981 Jun 1; 28(22):2469-75.
    View PubMed
  235. Adler C, Keren O, Korczyn AD. Tolerance to the Mydriatic effects of morphine in mice. J Neural Transm. 1980; 48(1):43-7.
    View PubMed
  236. Klemfuss H, Tallarida RJ, Adler CH, Adler MW. Morphine-induced mydriasis and fluctuation in the rat: time and dose relationships. Journal of Pharmacology & Experimental Therapeutics. 1979 Jan; 208(1):91-5.
    View PubMed
  237. Adler MW, Adler CH. Toxicity to heavy metals and relationship to seizure thresholds. Clin Pharmacol Ther. 1977 Nov; 22(5 Pt 2):774-9.
    View PubMed